fda semaglutide warning news october 2025 Novo Nordisk expands legal action to protect US patients from unsafe, non- FDA-approved compounded "semaglutide" U.S. FDA finds no evidence

Because the medication does not encourage sustainable, positive lifestyle change, its common to regain the weight after stopping the medication

This model eliminates the need for waiting rooms and allows for consistent, ongoing support

Proper preparation of your environment significantly reduces the risk of introducing contaminants that could compromise the safety of your medication or cause injection site reactions

Most people find that a seven-day gap between their final dose of Mounjaro and their first dose of Wegovy is enough to reduce the risk of overlapping side effects, such as bloating and nausea

GLP-1 medications can help offset some of these changes